Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.repc.2023.10.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reply to: RAAS inhibitors in COVID-19: Not all are created equal. Telmisartan is the one.
Rev Port Cardiol
April 2024
Laboratório de Farmacologia, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal; Mechanistic Pharmacology and Pharmacotherapy Unit, UCIBIO-i4HB, Faculty of Pharmacy, University of Porto, Porto, Portugal.
Reply to: RAAS inhibitors in COVID-19: Not all are created equal!
Rev Port Cardiol
September 2023
Laboratório de Farmacologia, Faculdade de Farmácia, Universidade do Porto, Portugal; Mechanistic Pharmacology and Pharmacotherapy Unit, UCIBIO-i4HB, Faculty of Pharmacy, University of Porto, Porto, Portugal.
In Reply: ACEI and ARB - Each Unique RAAS Inhibitors: The Importance of Impact on Inflammation.
Mayo Clin Proc
February 2023
Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.
RAAS Inhibitors and Risk of Covid-19. Reply.
N Engl J Med
November 2020
University of Milano-Bicocca, Milan, Italy
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!